Keyphrases
Netherlands
100%
Cancer Registry
100%
Advanced Breast Cancer
100%
HER2+
100%
HER2-positive Advanced Breast Cancer
100%
Pertuzumab
100%
T-DM1
100%
Hormone Receptor
75%
HER2-targeted Therapy
62%
Implementation Outcomes
37%
Adjusted Hazard Ratio
37%
Median Overall Survival
25%
Multivariable
12%
Patient Survival
12%
Survival Rate
12%
Kaplan-Meier Method
12%
Human Epidermal Growth Factor Receptor 2 (HER2)
12%
Competing Risks
12%
Receptor Subtypes
12%
Regression Modeling
12%
Cox Proportional Hazards Regression
12%
Risk Method
12%
Real-world Overall Survival
12%
INIS
patients
100%
cancer
100%
netherlands
100%
breasts
100%
receptors
63%
therapy
54%
hormones
54%
implementation
45%
diseases
36%
hazards
36%
humans
9%
risks
9%
modeling
9%
market
9%
growth factors
9%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Cancer Registry
100%
Pertuzumab
100%
Hormone Receptor
85%
Disease
57%
Overall Survival
42%
Survival Rate
14%
Epidermal Growth Factor Receptor 2
14%
Gamma Urogastrone
14%
Receptor Subtype
14%
Neuroscience
Hormone Receptor
100%
Pertuzumab
100%
Gamma Urogastrone
16%
Epidermal Growth Factor Receptor 2
16%
Receptor Subtype
16%
Agricultural and Biological Sciences
Hormone Receptor
100%
Pertuzumab
100%
Survival Rate
16%
Epidermal Growth Factor Receptor
16%